New bicyclicpyridine derivatives
US-2015368256-A1 · Dec 24, 2015 · US
Activators and therapeutic applications thereof
US10214491B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10214491-B2 |
| Application number | US-201414171845-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 4, 2014 |
| Priority date | Jun 20, 2007 |
| Publication date | Feb 26, 2019 |
| Grant date | Feb 26, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention presents methods of identifying small molecule compounds that are activators of tumor suppressor protein p53 pathway, and its associated family members p63 and p73, function. The invention is further drawn to methods of killing tumor cells and treating cancers or other conditions requiring activation of the p53 family member pathways and DNA damage response pathways with the small molecules.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating cancer, comprising administering to a patient in need thereof a therapeutically effective amount of a compound having the formula: or a pharmaceutically acceptable salt thereof. 2. The method according to claim 1 , wherein the compound is administered in a dose in a range of about 0.001 mg/kg to about 200 mg/kg per day. 3. The method according to claim 1 , wherein the compound is administered orally, parenterally, subligually, transdermally, rectally, transmucosally, topically, via inhalation, or via buccal administration.
Assignees
Inventors
Classifications
4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine · CPC title
- C07D215/54Primary
attached in position 3 · CPC title
with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms · CPC title
attached in position 4 · CPC title
Quinolines; Isoquinolines · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10214491B2 cover?
- The invention presents methods of identifying small molecule compounds that are activators of tumor suppressor protein p53 pathway, and its associated family members p63 and p73, function. The invention is further drawn to methods of killing tumor cells and treating cancers or other conditions requiring activation of the p53 family member pathways and DNA damage response pathways with the small…
- Who is the assignee on this patent?
- Univ Johns Hopkins
- What technology area does this patent fall under?
- Primary CPC classification C07D215/54. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).